Evidence map›Paper›PMID 40595613›Full record

ArticleNPJ breast cancer2025

Regular aspirin use, breast tumor characteristics and long-term breast cancer survival.

Cheng Peng, Tengteng Wang, Michelle D Holmes, Wendy Y Chen, Kristen D Brantley, Phuong Anh Le, Yujing J Heng, Pepper J Schedin, Bernard A Rosner, Walter C Willett and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Cheng PengChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA. recpe@channing.harvard.edu.
Tengteng WangRutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Michelle D HolmesChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Wendy Y ChenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kristen D BrantleyChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Phuong Anh LeDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Yujing J HengDepartment of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Pepper J SchedinDepartment of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA.
Bernard A RosnerChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Walter C WillettChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Meir J StampferChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Rulla M TamimiDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
A Heather EliassenChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Funding

Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, TAMIMI, RULLA M · 2000 to 2019
$77.8M
Risk Factors for Breast Cancer in Younger NursesR01CA050385 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 1989 to 2019
$32.3M
Life Course Cancer Epidemiology Cohort in WomenU01CA176726 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 2018 to 2025
$22.4M
Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
Training Program in Cancer EpidemiologyT32CA009001 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI A. Heather Eliassen, Meir Stampfer · 1985 to 2026
$17.3M
Premonopausal Hormone Levels and Risk of Breast CancerR01CA067262 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HANKINSON, SUSAN E · 2002 to 2011
$11.9M
BIOCHEMICAL MARKERS IN THE NURSES'HEALTH STUDY COHORTR01CA049449 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HANKINSON, SUSAN E · 1989 to 2008
$11.3M
Epidemiologic StudiesU19CA148065 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI AHSAN, HABIBUL, BRUGGE, JOAN SIEFERT · 2010 to 2014
$10.6M
NSAIDs During Postpartum Involution for Breast Cancer ChemopreventionR01CA169175 · NCI · UNIVERSITY OF COLORADO DENVER · PI SCHEDIN, PEPPER J · 2013 to 2024
$4.8M
Assessing the role of androgens in breast cancer riskR01CA166666 · NCI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI HANKINSON, SUSAN E · 2012 to 2015
$1.7M
Living beyond cancer: the short- and long-term cognitive effects of breast cancer and its treatment for cancer survivorsK01AG080030 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI Cheng Peng · 2023 to 2026
$524k
NCI NIH HHS P01 CA087969NCI NIH HHS P01 CA87969NCI NIH HHS R01 CA049449NCI NIH HHS R01 CA050385NCI NIH HHS R01 CA067262NCI NIH HHS R01 CA166666NCI NIH HHS R01 CA169175NCI NIH HHS R01 CA50385NCI NIH HHS T32 CA009001NCI NIH HHS U01 CA176726NCI NIH HHS U19 CA148065NCI NIH HHS UM1 CA186107NIA NIH HHS K01 AG080030NIA NIH HHS K01AG080030
6 · The paper itself

Abstract

Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.

Identifiers

PMID40595613
PMCPMC12216965

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.